Curis (CRIS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
5 Jun, 2026Executive summary
A special meeting will be held virtually on June 25, 2026, to vote on a reverse stock split and a potential adjournment proposal.
The reverse stock split would combine issued shares at a ratio between 1-for-5 and 1-for-25, as determined by the board within six months of approval.
The primary goal is to increase the share price to meet Nasdaq listing requirements and avoid delisting.
The board recommends voting in favor of both proposals.
Voting matters and shareholder proposals
Proposal 1 seeks approval for amendments to effect a reverse stock split at a ratio between 1-for-5 and 1-for-25, with the board having discretion on timing and ratio.
Proposal 2 allows adjournment of the meeting to solicit more proxies if needed for Proposal 1.
Only these two proposals will be considered at the meeting; no other business will be transacted.
Each share entitles the holder to one vote; a majority of votes cast is required for approval.
Stockholder proposals for the 2027 annual meeting must be submitted by December 22, 2026, for inclusion in the proxy statement.
Board of directors and corporate governance
The board retains authority to abandon the reverse stock split even after stockholder approval if deemed not in the best interest of the company.
The board will determine the exact ratio and timing of the reverse split and will publicly announce the decision.
Latest events from Curis
- Net loss increased, cash runway is short, and additional funding is urgently needed to sustain operations.CRIS
Q2 2026 - Best-efforts offering seeks up to $13.6M for R&D, but going concern risk and dilution remain high.CRIS
Registration filing - Emavusertib delivers superior efficacy and safety in hematologic cancers, advancing toward approval.CRIS
Corporate presentation - Emavusertib plus BTKi achieves strong PCNSL responses and advances, pending further funding.CRIS
Study update - Reverse stock split and adjournment proposals were both approved by majority vote.CRIS
EGM 2026 - Emavusertib shows superior efficacy and safety in lymphoma and AML, with broad expansion plans.CRIS
Corporate presentation - Q3 net loss narrowed, emavusertib data positive, but funding needed beyond mid-2025.CRIS
Q3 2024 - Emavusertib gains EU ODD as Q2 net loss hits $11.8M and cash runway extends into Q1 2025.CRIS
Q2 2024 - Emavusertib advances on accelerated approval path with strong data, improved financials, and funding risks.CRIS
Q4 2024